LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patientswmm2022-12-29T21:19:31-08:00June 4th, 2022|Read more
Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?wmm2023-01-08T18:20:36-08:00May 30th, 2022|Read more
Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myelomaInvivoscribe Marketing2022-09-07T22:22:23-07:00May 3rd, 2022|Read more
Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patientswmm2022-01-06T05:38:03-08:00January 4th, 2022|Read more
NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLLwmm2022-01-08T23:37:03-08:00December 28th, 2021|Read more
Roswell Park Comprehensive Cancer Center Licenses Invivoscribe’s LymphoTrack Software for Plug and Play Pipeline UseInvivoscribe Marketing2021-09-02T16:53:40-07:00September 2nd, 2021|Read more
Invivoscribe Announces Key Submission in the EU, Expanded Presence and Activity in ChinaInvivoscribe Marketing2021-07-22T17:27:56-07:00July 22nd, 2021|Read more
Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune Systemwmm2021-06-24T18:20:34-07:00June 24th, 2021|Read more
Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and Chinawmm2021-06-03T20:36:18-07:00June 3rd, 2021|Read more
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United StatesInvivoscribe Marketing2021-02-26T19:09:52-08:00May 19th, 2020|Read more